Mycophenolate Mofetil Sandoz (Mycophenolate Mofetil)

Mycophenolate Mofetil is used to modulate immune activity in conditions where excessive lymphocyte proliferation is harmful.

• Organ transplant rejection: helps prevent acute rejection episodes in kidney, heart and liver transplants.
• Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus.
• Graft‑versus‑host disease prophylaxis: used in some protocols to lower the incidence of GVHD after hematopoietic stem cell transplantation.

• Mycophenolate Mofetil is converted intracellularly to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This blocks de novo guanosine nucleotide synthesis, a pathway essential for proliferation of T and B lymphocytes, thereby reducing immune cell activation and antibody production.

Adverse reactions may occur with Mycophenolate Mofetil therapy.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: frequent loose stools.
• Headache: transient cranial discomfort.
• Infections: increased susceptibility to bacterial, viral or fungal infections.
• Leukopenia: reduced white blood cell count.
• Anemia: lowered red blood cell levels.

Serious or Rare Side Effects

• Severe infection: opportunistic infections such as Pneumocystis jirovecii pneumonia.
• Bone marrow suppression: pancytopenia requiring medical intervention.
• Renal impairment: elevated serum creatinine or reduced glomerular filtration rate.
• Hepatotoxicity: abnormal liver enzymes or hepatitis.
• Malignancy: increased risk of post‑transplant lymphoproliferative disorders.

Patients receiving Mycophenolate Mofetil should be monitored closely for safety concerns.

• Blood counts: perform regular complete blood count to detect leukopenia or anemia.
• Renal function: monitor serum creatinine and eGFR periodically.
• Live vaccines: avoid administration due to heightened infection risk.
• Pregnancy: assess risks and benefits; use only if clearly needed.
• Dose adjustments: consider hepatic impairment when titrating therapy.
• Store at below 25°C: keep in the original pack, protect from moisture.

Mycophenolate Mofetil can interact with several drug classes, affecting efficacy or safety.

Major Interactions (Avoid)

• Antimetabolites (e.g., azathioprine): additive immunosuppression may increase infection risk.
• Live vaccines: concurrent use can lead to severe infection.
• Rifampin or other strong inducers: markedly reduce mycophenolate exposure.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole): may increase mycophenolate levels.
• ACE inhibitors or ARBs: monitor renal function as combined effect can worsen kidney parameters.
• Non‑live vaccines: immune response may be attenuated; assess serologic protection.